Inno-Gene SA
WSE:IGN
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
N/A
N/A
|
| Price Target |
|
We'll email you a reminder when the closing price reaches PLN.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Inno-Gene SA
Accrued Liabilities
Inno-Gene SA
Accrued Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Accrued Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
I
|
Inno-Gene SA
WSE:IGN
|
Accrued Liabilities
zł85k
|
CAGR 3-Years
-65%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
M
|
Medicofarma Biotech SA
WSE:MDB
|
Accrued Liabilities
zł1.3m
|
CAGR 3-Years
215%
|
CAGR 5-Years
73%
|
CAGR 10-Years
N/A
|
|
|
R
|
Ryvu Therapeutics SA
WSE:RVU
|
Accrued Liabilities
zł11.3m
|
CAGR 3-Years
21%
|
CAGR 5-Years
46%
|
CAGR 10-Years
13%
|
|
|
S
|
Selvita SA
WSE:SLV
|
Accrued Liabilities
zł8.1m
|
CAGR 3-Years
-24%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Inno-Gene SA
Glance View
Inno Gene SA engages in the management of startup biotechnology companies. The company is headquartered in Poznan, Woj. Wielkopolskie. The company went IPO on 2011-02-08. Inno-Gene SA’s portfolio comprises of Centrum Badan DNA Sp. z o.o., a company that provides services in the field of genetic medical diagnostics, including microbiological diagnosis of infection and the suitability of human congenital diseases using tests performed on DNA microarray technology. On March 22, 2013, the Company established a new subsidiary, Centrum Edukacji Bio-Medycznej Sp. z o.o. On April 11, 2013, the Company established two new indirect subsidiaries, Genomix Sp. z o.o. and Madgenetix Sp. z o.o. In addition, it operates through VitainSillica Sp z o o.
See Also
What is Inno-Gene SA's Accrued Liabilities?
Accrued Liabilities
85k
PLN
Based on the financial report for Jun 30, 2024, Inno-Gene SA's Accrued Liabilities amounts to 85k PLN.
What is Inno-Gene SA's Accrued Liabilities growth rate?
Accrued Liabilities CAGR 3Y
-65%
Over the last year, the Accrued Liabilities growth was 0%. The average annual Accrued Liabilities growth rates for Inno-Gene SA have been -65% over the past three years .
You don't have any saved screeners yet
